Skip to main content
NervGen Pharma Corp. logo

NervGen Pharma Corp. — Investor Relations & Filings

Ticker · NGEN ISIN · CA64082X2032 LEI · 549300CZ6Y0WSURPE203 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 325 across all filing types
Latest filing 2026-04-25 AGM Information
Country CA Canada
Listing TSXV NGEN

About NervGen Pharma Corp.

https://nervgen.com/

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on the discovery and development of pharmaceutical treatments designed to promote nervous system repair following neurologic trauma and disease. The company's core mission is to enable the nervous system to repair itself, offering a pharmacologic approach to conditions previously considered irreparable. Its lead drug candidate is NVG-291, a novel therapy currently in Phase 1b/2a clinical trials (CONNECT SCI Study) for individuals living with chronic spinal cord injury (SCI). Recent study data has demonstrated durable improvements in function and quality of life in this patient population. NervGen is also advancing its next-generation candidate, NVG-300, into preclinical proof-of-concept studies for three initial indications, expanding its pipeline for nervous system disorders.

Recent filings

Filing Released Lang Actions
Other securityholders documents - English.pdf
AGM Information Classification · 72% confidence The document is the extract of minutes from the Annual General Meeting (AGM) held April 23, 2026, detailing the shareholder resolution to amend the corporation’s articles and appending the amended Articles of Incorporation. It is not a full annual report or financial statement, nor a proxy circular solicitation (even though it references the circular), but rather the AGM meeting minutes itself, which falls squarely under AGM Information (AGM-R).
2026-04-25 English
Other securityholders documents - English.pdf
Governance Information Classification · 80% confidence The document is an extract of minutes from the annual general meeting and full text of the Company’s amended Articles of Incorporation (governance charter changes), detailing internal rules (quorum requirements) and the corporate governance structure. This is not a financial report, proxy solicitation summary only, earnings release, or regulatory notice, but rather the core governance document itself. Therefore it should be classified as Governance Information (CGR).
2026-04-25 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled “Report of Voting Results” and details the outcomes of votes at the Company’s annual general meeting (e.g., election of directors, appointment of auditors, approval of equity plans, amendments to articles) in accordance with continuous disclosure rules. It is not a summary or presentation but the formal declaration of shareholder voting results. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-25 English
Report of voting results.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document provides the detailed voting results for matters considered at the Company’s annual general meeting (number of directors, election of directors, appointment of auditors, plan approvals, amendment of articles). It is not the meeting materials or an investor presentation but specifically the official report of shareholder voting outcomes. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-04-25 English
News release - English.pdf
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing successful End-of-Phase 2 interactions with the FDA and outlining the design of a Phase 3 registrational study. It is not reporting financial results (so not ER, IR, or 10-K), not a call transcript, not governance or board changes, not a dividend or share action, nor a proxy or voting announcement. It does not present detailed financial statements or an investor presentation, nor is it a formal regulatory form submission. It is general company news with forward-looking statements, fitting the fallback category for miscellaneous regulatory or company announcements. Therefore, it aligns with the Regulatory Filings (RNS) category.
2026-04-07 English
News release - English.pdf
Regulatory Filings Classification · 62% confidence The document is a corporate press release announcing the completion of an End-of-Phase 2 meeting with the FDA and alignment on the Phase 3 RESTORE trial design. It provides clinical and regulatory study details, timeline, and forward-looking statements. It does not present financial results (ER, IR), an investor presentation (IP), management or proxy materials, board changes, dividends, share transactions, or a formal report (e.g., 10-K/IR). It is a general regulatory/operational update to the market, fitting the fallback category for miscellaneous regulatory announcements.
2026-04-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.